Binge Eating and Appetite Signals
Binge eating is distinct from ordinary overeating, with its own recognisable pattern and appetite signalling disruption....
block further down, and Blade's raw-block scanner pairs an // inline β swallowing 140 lines of the article. $isDraftPreview = $isDraftPreview ?? false; @endphp
Leptin should signal fullness as fat increases, but in obesity that signal often stops working. Here is the physiology behind that counterintuitive problem.
Our guide to why you're always hungry touched on several appetite-related hormones. Leptin deserves its own dedicated explanation, since understanding it directly addresses one of the most persistent misunderstandings about why obesity is genuinely difficult to overcome through willpower alone.
Leptin is produced by fat tissue itself, and it signals to the brain, specifically the hypothalamus, how much energy is stored in the body. Its intended role is straightforward: as fat stores increase, leptin levels rise, and the brain should respond by reducing appetite and increasing energy expenditure, a natural system designed to keep body fat within a stable range.
Here is where the system breaks down in obesity, and where the term "leptin resistance" comes from. People with obesity typically have higher, not lower, circulating leptin levels, exactly as the system's basic logic would predict given increased fat mass. But the expected result, reduced appetite, does not follow. The brain, specifically the relevant hypothalamic circuits, becomes resistant to leptin's signal, similar in concept to how insulin resistance means cells stop responding properly to insulin despite its presence.
The practical result: someone with leptin resistance can have high fat stores and high leptin levels while their brain continues receiving a signal more consistent with fat depletion, driving continued hunger and reduced energy expenditure despite the body objectively having ample stored energy.
This is a genuinely important piece of physiology for reframing how obesity should be understood. It is not that people with obesity lack a fullness signal; leptin is present, often in higher amounts than in someone at a healthy weight. The problem is that the signal is not being properly received and acted upon by the brain, a physiological malfunction rather than a personal failing to listen to a signal that is working normally.
The exact mechanisms are an active area of research, but contributing factors are thought to include chronic inflammation, covered in our related guide on GLP-1 and inflammation, impaired leptin transport across the blood-brain barrier, and changes within the hypothalamic signalling pathways themselves that develop over time with sustained excess fat mass.
Weight loss is associated with improvement in leptin sensitivity for many people, though this is not immediate or guaranteed to fully normalise, and it is part of why sustained weight loss can become somewhat easier over time for some people as the underlying signalling improves, while remaining genuinely difficult during the initial period when resistance is still substantially present.
GLP-1 medications work through a different, complementary appetite pathway rather than directly correcting leptin resistance itself, which is part of why they can produce meaningful appetite reduction even while underlying leptin resistance may still be present, offering a route to appetite control that does not depend on leptin signalling working properly.
Understanding leptin resistance helps explain, consistent with how the WHO frames obesity as a complex condition with genuine physiological drivers rather than simply a behavioural choice, why sustained hunger despite adequate or excess energy stores is a real physiological experience for many people with obesity, not a sign of weak willpower, which matters both for self-understanding and for how weight management support should be approached.
GLP-1 pathway support delivered as drops works through a complementary appetite pathway that can provide meaningful appetite support even where leptin resistance remains a factor. METASLIMβ’ is a physician-reviewed sublingual supplement, and understanding the physiology behind persistent hunger is part of why physician-guided appetite support, rather than willpower alone, is often the more effective approach.
Check the current price and what's included as part of understanding your options with this physiology in mind.
Leptin is a fullness hormone produced by fat tissue, with levels rising, not falling, as body fat increases, as the system's basic design would predict.
In obesity, the brain often stops responding properly to leptin's signal, a state called leptin resistance, despite genuinely elevated circulating levels.
This means persistent hunger in obesity often reflects a real signalling malfunction, not a failure to listen to a normally functioning fullness cue.
GLP-1 medications work through a complementary pathway that can provide appetite support independent of whether leptin resistance is present.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.
METASLIMβ’ is a physician-guided GLP-1 sublingual program β injection-free appetite support, designed for sustainable weight loss.
Leptin is a hormone produced by fat tissue that signals to the brain how much energy is stored in the body. It is meant to reduce appetite and increase energy expenditure as fat stores, and therefore leptin levels, rise.
This is explained partly by leptin resistance: people with obesity typically have high leptin levels, but the brain becomes resistant to that signal, continuing to drive hunger despite objectively ample stored energy.
They are different hormones and pathways, but conceptually similar: both involve the body producing adequate or high levels of a signalling hormone while the relevant tissue, the brain for leptin, cells generally for insulin, stops responding properly to it.
Weight loss is associated with some improvement in leptin sensitivity for many people, though it is not immediate or guaranteed to fully normalise, which is part of why the earlier stages of weight loss can feel harder than later progress for some people.
Not directly. GLP-1 medications work through a different, complementary appetite pathway, which is part of why they can provide meaningful appetite support even while underlying leptin resistance remains present.
It is genuine evidence that persistent hunger in obesity often reflects a real physiological signalling malfunction, not simply weak willpower, which is an important part of understanding why obesity is often genuinely difficult to address through diet and effort alone.
The exact mechanisms are still being researched, but contributing factors are thought to include chronic inflammation, impaired leptin transport to the brain, and changes within the brain's own signalling pathways that develop over time with sustained excess fat mass.